| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DKK 4 |
| Uniprot No | Q9UBT3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-224aa |
| 氨基酸序列 | LVLDFNNIRSSADLHGARKGSQCLSDTDCNTRKFCLQPRDEKPFCATCRGLRRRCQRDAMCCPGTLCVNDVCTTMEDATPILERQLDEQDGTHAEGTTGHPVQENQPKRKPSIKKSQGRKGQEGESCLRTFDCGPGLCCARHFWTKICKPVLLEGQVCSRRGHKDTAQAPEIFQRCDCGPGLLCRSQLTSNRQHARLRVCQKIEKL |
| 预测分子量 | 27.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于 **DKK4重组蛋白** 的3条参考文献示例(内容基于领域内常见研究方向构造，供参考)：
---
1. **文献名称**：*"Recombinant DKK4 Protein Inhibits Wnt/β-Catenin Signaling in Colorectal Cancer Cells"*
**作者**：Chen et al.
**摘要**：研究通过表达并纯化人源DKK4重组蛋白，发现其能够特异性结合LRP5/6受体，抑制Wnt/β-catenin信号通路，从而抑制结直肠癌细胞增殖和迁移，提示DKK4可能作为潜在抗癌靶点。
2. **文献名称**：*"Expression and Functional Characterization of DKK4 Recombinant Protein in Stem Cell Maintenance"*
**作者**：Wang et al.
**摘要**：利用哺乳动物细胞系统成功表达具有生物活性的DKK4重组蛋白，并证明其通过拮抗Wnt信号调控肠道干细胞的自我更新，为组织再生研究提供工具。
3. **文献名称**：*"Structural Analysis of Recombinant DKK4 Reveals Its Role in Tumor Microenvironment Remodeling"*
**作者**：Kimura et al.
**摘要**：通过冷冻电镜解析DKK4重组蛋白的结构，阐明其与微环境基质蛋白的相互作用机制，发现DKK4可通过调节基质硬度促进肿瘤耐药性，为靶向治疗提供依据。
---
如需真实文献，建议在 **PubMed** 或 **Google Scholar** 中检索关键词“DKK4 recombinant protein”或“DKK4 Wnt signaling”。
**Background of DKK4 Recombinant Protein**
DKK4 (Dickkopf-related protein 4) is a member of the Dickkopf family of secreted glycoproteins, known for their role in modulating Wnt signaling pathways. The Wnt pathway is critical for embryonic development, tissue homeostasis, and cell proliferation, and its dysregulation is linked to cancers, bone diseases, and developmental disorders. DKK proteins typically act as antagonists of Wnt signaling by binding to low-density lipoprotein receptor-related proteins 5/6 (LRP5/6), co-receptors essential for canonical Wnt signal transduction. However, DKK4 exhibits context-dependent activity, functioning as either a Wnt inhibitor or activator depending on cellular conditions and receptor interactions.
DKK4 is expressed in specific tissues during embryogenesis, including the developing limbs, kidneys, and nervous system, suggesting roles in organogenesis. In adults, abnormal DKK4 expression is associated with cancers (e.g., colorectal, breast, and liver cancers), where it may promote tumor growth, metastasis, or drug resistance by disrupting Wnt-regulated processes. Its dual regulatory effects on Wnt signaling complicate its functional characterization, necessitating further research to clarify its mechanisms.
Recombinant DKK4 protein is produced using genetic engineering techniques, often in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications. Purified via affinity chromatography, the protein retains bioactivity for experimental applications, such as studying Wnt pathway dynamics, screening therapeutic agents, or exploring DKK4's role in disease models.
Current research focuses on DKK4's potential as a diagnostic biomarker or therapeutic target, particularly in cancers with aberrant Wnt signaling. Challenges include understanding its tissue-specific roles and resolving conflicting data on its pro- or anti-tumor effects. Recombinant DKK4 serves as a vital tool in these investigations, bridging molecular insights to potential clinical applications.
×
